Park Place Capital’s Charles River Laboratories CRL Stock Holding History

Park Place Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42K	Sell	185 -10	-5%	-$1.78K	0.01%	455
2026 Q1	$33.6K	Hold	195	–	–	0.01%	414
2025 Q4	$38.9K	Buy	195 +10	+5%	+$1.81K	0.01%	363
2025 Q3	$28.9K	Hold	185	–	–	0.01%	408
2025 Q2	$28.6K	Sell	185 -24	-11%	-$3.2K	0.01%	429
2025 Q1	$31.5K	Hold	209	–	–	0.01%	396
2024 Q4	$38.6K	Sell	209 -264	-56%	-$50.9K	0.01%	388
2024 Q3	$93.2K	Sell	473 -5	-1%	-$1.04K	0.03%	293
2024 Q2	$98.7K	Sell	478 -52	-10%	-$11.8K	0.03%	278
2024 Q1	$144K	Buy	530 +14	+3%	+$3.34K	0.05%	272
2023 Q4	$122K	Sell	516 -337	-40%	-$66.3K	0.05%	278
2023 Q3	$167K	Sell	853 -8	-0.9%	-$1.64K	0.05%	260
2023 Q2	$181K	Buy	861 +16	+2%	+$3.18K	0.05%	258
2023 Q1	$171K	Buy	845 +28	+3%	+$6.35K	0.05%	264
2022 Q4	$178K	Buy	+817	New	+$178K	0.05%	256

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Park Place Capital's CRL Position: Q2 2026 in Review

Park Place Capital reduced its Charles River Laboratories (CRL) stake by 5.1% in Q2 2026, selling an estimated $1.78K and leaving 185 shares worth $42K. The position accounts for 0.01% of the portfolio, ranked #455.

Park Place Capital first reported a position in CRL in Q4 2022 and has held it in 15 quarters since. The position peaked at $181K in Q2 2023. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Park Place Capital held 185 shares of Charles River Laboratories worth $42K as of Q2 2026.
Park Place Capital sold 10 Charles River Laboratories shares in Q2 2026, an estimated $1.78K.
Charles River Laboratories made up 0.01% of Park Place Capital's portfolio in Q2 2026, its #455 holding.
Park Place Capital first reported a position in Charles River Laboratories in Q4 2022 and has held it in 15 quarters since.
Park Place Capital's Charles River Laboratories position peaked at $181K in Q2 2023.
563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.